Linked Life Data

6365945

Source:http://linkedlifedata.com/resource/pubmed/id/6365945

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6365945rdf:typepubmed:Citationlld:pubmed
pubmed-article:6365945lifeskim:mentionsumls-concept:C0011854lld:lifeskim
pubmed-article:6365945lifeskim:mentionsumls-concept:C0443315lld:lifeskim
pubmed-article:6365945lifeskim:mentionsumls-concept:C0021641lld:lifeskim
pubmed-article:6365945lifeskim:mentionsumls-concept:C0021655lld:lifeskim
pubmed-article:6365945lifeskim:mentionsumls-concept:C0549178lld:lifeskim
pubmed-article:6365945lifeskim:mentionsumls-concept:C1552428lld:lifeskim
pubmed-article:6365945lifeskim:mentionsumls-concept:C1555985lld:lifeskim
pubmed-article:6365945lifeskim:mentionsumls-concept:C0547047lld:lifeskim
pubmed-article:6365945pubmed:issue4lld:pubmed
pubmed-article:6365945pubmed:dateCreated1984-4-20lld:pubmed
pubmed-article:6365945pubmed:abstractTextThe influence of continuous sc insulin infusion therapy for 6 weeks on sensitivity to insulin (euglycemic clamp technique) and hepatic glucose production (3-[3H]glucose technique) was measured in 10 type 1 diabetic patients whose mean duration of diabetes was 8 yr. Mean diurnal blood glucose fell from 8.5 +/- 0.8 (SEM) mmol/liter to 6.0 +/- 0.6 mmol/liter (P less than 0.05) and glycosylated hemoglobin from 10.5 +/- 0.4% to 8.7 +/- 0.3%. Insulin requirements declined by 23% from 47 +/- 4 U/day prepump to 36 +/- 2 U/day after 6 weeks of pump therapy (P less than 0.01). During the insulin clamp, plasma insulin was maintained at approximately 90 mU/liter and plasma glucose at approximately 5.0 mmol/liter in all studies. The rate of glucose metabolism in diabetic patients during conventional therapy (4.65 +/- 0.41 mg/kg X min) was 35% lower than in normal subjects (7.20 +/- 0.42 mg/kg X min, n = 14, P less than 0.001). After 6 weeks of pump therapy, total glucose uptake increased by 27% to 5.90 +/- 0.60 mg/kg X min, P less than 0.05 vs. prepump). This was still 18% lower than in the normal subjects (P less than 0.05). Basal hepatic glucose production in the diabetic patients during conventional therapy (3.07 +/- 0.14 mg/kg X min) was 70% higher than in the normal subjects (1.79 +/- 0.07 mg/kg X min, n = 7, P less than 0.001). After 6 weeks of pump therapy, hepatic glucose production fell to 2.48 +/- 0.19 mg/kg X min (P less than 0.05), which was still 40% higher than in the normal subjects (P less than 0.01). Basal hepatic glucose production was directly related to the fasting plasma glucose level (r = 0.67, P less than 0.001) and inversely proportional to fasting insulin concentration (r = -0.48, P less than 0.05) in the diabetic patients. Specific tracer insulin binding to erythrocytes in the diabetic patients (19.4 +/- 1.5%) was comparable to that in the normal subjects (19.6 +/- 1.2%) and remained unchanged during pump therapy. Thus the improved metabolic control resulting from pump therapy is associated with enhancement in sensitivity to insulin, and reduction in basal hepatic glucose production.lld:pubmed
pubmed-article:6365945pubmed:languageenglld:pubmed
pubmed-article:6365945pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6365945pubmed:citationSubsetAIMlld:pubmed
pubmed-article:6365945pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6365945pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6365945pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6365945pubmed:statusMEDLINElld:pubmed
pubmed-article:6365945pubmed:monthAprlld:pubmed
pubmed-article:6365945pubmed:issn0021-972Xlld:pubmed
pubmed-article:6365945pubmed:authorpubmed-author:KoivistoV AVAlld:pubmed
pubmed-article:6365945pubmed:authorpubmed-author:Yki-JärvinenH...lld:pubmed
pubmed-article:6365945pubmed:issnTypePrintlld:pubmed
pubmed-article:6365945pubmed:volume58lld:pubmed
pubmed-article:6365945pubmed:ownerNLMlld:pubmed
pubmed-article:6365945pubmed:authorsCompleteYlld:pubmed
pubmed-article:6365945pubmed:pagination659-66lld:pubmed
pubmed-article:6365945pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:6365945pubmed:meshHeadingpubmed-meshheading:6365945-...lld:pubmed
pubmed-article:6365945pubmed:meshHeadingpubmed-meshheading:6365945-...lld:pubmed
pubmed-article:6365945pubmed:meshHeadingpubmed-meshheading:6365945-...lld:pubmed
pubmed-article:6365945pubmed:meshHeadingpubmed-meshheading:6365945-...lld:pubmed
pubmed-article:6365945pubmed:meshHeadingpubmed-meshheading:6365945-...lld:pubmed
pubmed-article:6365945pubmed:meshHeadingpubmed-meshheading:6365945-...lld:pubmed
pubmed-article:6365945pubmed:meshHeadingpubmed-meshheading:6365945-...lld:pubmed
pubmed-article:6365945pubmed:meshHeadingpubmed-meshheading:6365945-...lld:pubmed
pubmed-article:6365945pubmed:meshHeadingpubmed-meshheading:6365945-...lld:pubmed
pubmed-article:6365945pubmed:meshHeadingpubmed-meshheading:6365945-...lld:pubmed
pubmed-article:6365945pubmed:meshHeadingpubmed-meshheading:6365945-...lld:pubmed
pubmed-article:6365945pubmed:meshHeadingpubmed-meshheading:6365945-...lld:pubmed
pubmed-article:6365945pubmed:meshHeadingpubmed-meshheading:6365945-...lld:pubmed
pubmed-article:6365945pubmed:year1984lld:pubmed
pubmed-article:6365945pubmed:articleTitleContinuous subcutaneous insulin infusion therapy decreases insulin resistance in type 1 diabetes.lld:pubmed
pubmed-article:6365945pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6365945pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6365945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6365945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6365945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6365945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6365945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6365945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6365945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6365945lld:pubmed